CICC International: Maintain Buy rating on Genting Hong Kong (01952.HK), promising overseas development prospects.

According to the Wisdom Financial APP, CICC International released a research report stating that Yun Dingxin Yao (01952.HK) has reached authorization/ asset acquisition agreements with several Chinese mainland pharmaceutical companies, introducing a number of heavyweight products in the fields of self-free/kidney, cardiovascular, and ophthalmology. The bank is optimistic about the overseas market potential and indications of EVER001, as well as the expansion potential of the commercial product portfolio and platform in mainland China, and maintains a buy rating.